سامانه جستجوی جامع منابع دانشگاه علوم پزشکی جندی شاپور اهواز



عنوان مقاله کنفرانس : M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on

ناشر : BMJ Publishing Group Ltd and British Thoracic Society

DOI کد :

10.1136/thoraxjnl-2017-210983.477

سال انتشار : 2017

نوع : مقاله کنفرانس

لینک خروجی به مقاله کنفرانس

@incollection{1,
    doi = {10.1136/thoraxjnl-2017-210983.477},
    url = {http://dx.doi.org/10.1136/thoraxjnl-2017-210983.477},
    year = 2017,
    publisher = {BMJ Publishing Group Ltd and British Thoracic Society},
    pages = {},
    author = {},
    title = {M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on}
}
TY  - DATA
DO  - 10.1136/thoraxjnl-2017-210983.477
UR  - http://dx.doi.org/10.1136/thoraxjnl-2017-210983.477
TI  - M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on
PY  - 2017
PB  - BMJ Publishing Group Ltd and British Thoracic Society
SP  - 
AU  -
, T. (2017). M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on. doi:10.1136/thoraxjnl-2017-210983.477
“M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on.” (2017)